Portrait
Kuan-Hung (Peter) Yeh
Ph.D. Candidate, Biomedical Informatics
University of California, San Diego
About Me

I am a Ph.D. candidate in Biomedical Informatics at the University of California, San Diego, advised by Dr. Ronghui Xu and Dr. Siddharth Singh. I am especially interested in how real-world evidence informs decisions across drug discovery, clinical development, and regulatory review.

My research focuses on statistical methodology and its application to causal inference to generate regulatory-grade real-world evidence. My dissertation spans both. Methodologically, I develop data-fusion methods for indirect treatment comparisons across randomized trials when head-to-head evidence is unavailable. In application, I conduct observational studies of treatment safety and effectiveness in gastroenterology, using large-scale claims and EHR data (Optum, Epic Cosmos) with target trial emulation, propensity score methods, and survival analysis.

I am currently an FDA-OCE-ASA Oncology Educational Fellow (2026–2027), one of 20 fellows selected nationwide. My work has appeared in Clinical Gastroenterology and Hepatology, JAMA Network Open, Alimentary Pharmacology & Therapeutics, Hypertension, and Annals of Surgical Oncology, among others.

Previously, I earned an M.S. in Biostatistics from UCLA and a B.S. in Public Health from National Taiwan University, and worked as a Biostatistician Intern at Foundation Medicine, Inc.

Curriculum Vitae
Education
  • University of California, San Diego
    University of California, San Diego
    Ph.D. in Biomedical Informatics
    2023 – Jun. 2028 (expected)
  • University of California, Los Angeles
    University of California, Los Angeles
    M.S. in Biostatistics
    2021 – 2023
  • National Taiwan University
    National Taiwan University
    B.S. in Public Health (Biostatistics Track)
    2016 – 2020
Honors & Awards
  • FDA-OCE-ASA Oncology Educational Fellow
    2026
  • NSF Travel Award, IMSI Workshop
    2026
  • Best Poster Presentation Award, 16th GI/Hepatology Annual Research Symposium, UCSD Health
    2025
  • J. Yang Scholarship, UCSD
    2023
  • Honor Graduate, Department of Public Health, NTU
    2020
  • Dr. K. P. Chen Memorial Scholarship, NTU
    2019
News
2026
Started the FDA-OCE-ASA Oncology Educational Fellowship (1 of 20 fellows nationwide).
Oct
First-author target trial emulation on adjunctive GLP-1 receptor agonists in IBD published in Clinical Gastroenterology and Hepatology.
Sep
Presented Trial Data Fusion: Indirect Comparisons Beyond Covariate Shift as a poster at the American Causal Inference Conference (ACIC) 2026.
Jun
Received an NSF Travel Award for the IMSI Workshop in Chicago.
May
Co-first-author paper on the comparative safety of advanced therapies for Crohn disease published in JAMA Network Open.
Feb
2025
Received the Best Poster Presentation Award at the 16th GI/Hepatology Annual Research Symposium, UCSD Health.
Jun
2024
Joined the Department of Biomedical Informatics, UCSD Health, as a Graduate Researcher.
Jan
2023
Started the Ph.D. program in Biomedical Informatics at UC San Diego.
Sep
Selected Publications (view all )
Adjunctive GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation
Adjunctive GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation

Yeh KH, Ahuja D, Patel SB, Xu R, Park S, ..., Singh S* (* corresponding author)

Clinical Gastroenterology and Hepatology. 2026.

Adjunctive GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation

Yeh KH, Ahuja D, Patel SB, Xu R, Park S, ..., Singh S* (* corresponding author)

Clinical Gastroenterology and Hepatology. 2026.

Comparative Safety of Advanced Therapies for Crohn Disease
Comparative Safety of Advanced Therapies for Crohn Disease

Park S, Ahuja D, Yeh KH†, Patel SB, Goodwin SW, ..., Singh S* († co-first author, * corresponding author)

JAMA Network Open. 2026;9(2):e2557922.

Comparative Safety of Advanced Therapies for Crohn Disease

Park S, Ahuja D, Yeh KH†, Patel SB, Goodwin SW, ..., Singh S* († co-first author, * corresponding author)

JAMA Network Open. 2026;9(2):e2557922.

Comparative Safety of Advanced Therapies in Patients with Ulcerative Colitis: An Administrative Claims-Based Study

Ahuja D, Dziegielewski C, Yeh KH†, Patel SB, Goodwin SW, ..., Singh S* († co-first author, * corresponding author)

American Journal of Gastroenterology. 2025.

Comparative Safety of Advanced Therapies in Patients with Ulcerative Colitis: An Administrative Claims-Based Study

Ahuja D, Dziegielewski C, Yeh KH†, Patel SB, Goodwin SW, ..., Singh S* († co-first author, * corresponding author)

American Journal of Gastroenterology. 2025.

Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases

Ahuja D, Yeh KH†, Patel SB, Lee HH, Goodwin SW, ..., Singh S* († co-first author, * corresponding author)

Clinical Gastroenterology and Hepatology. 2025.

Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases

Ahuja D, Yeh KH†, Patel SB, Lee HH, Goodwin SW, ..., Singh S* († co-first author, * corresponding author)

Clinical Gastroenterology and Hepatology. 2025.

Long-Term Outcomes of an Infliximab-First Versus Vedolizumab-First Treatment Strategy in Biologic-Naïve Patients with Ulcerative Colitis

Haynesworth A, Yeh KH†, Lee HH, Kirkpatrick M, ..., Singh S* († co-first author, * corresponding author)

Alimentary Pharmacology & Therapeutics. 2025;61(4):693-701.

Long-Term Outcomes of an Infliximab-First Versus Vedolizumab-First Treatment Strategy in Biologic-Naïve Patients with Ulcerative Colitis

Haynesworth A, Yeh KH†, Lee HH, Kirkpatrick M, ..., Singh S* († co-first author, * corresponding author)

Alimentary Pharmacology & Therapeutics. 2025;61(4):693-701.

All publications